Glyx Tablets
Glyx Tablet supports healthy blood sugar levels and improves insulin sensitivity. Formulated with key ingredients to aid glucose balance, antioxidant protection, and overall metabolic health.
₨ 1,000
Glyx Tablet is a dietary supplement formulated to support blood sugar regulation and enhance insulin sensitivity. It is designed to complement healthy lifestyle and dietary management for individuals seeking balanced glucose metabolism.
Key Active Ingredients
Bryophyllum Pinnatum Extract Supports blood sugar balance and beta-cell protection.
Fenugreek Extract Helps reduce glucose absorption and supports HbA1c control.
Alpha-Lipoic Acid Supports nerve health and reduces oxidative stress.
Chromium Picolinate Enhances insulin receptor activity and glucose uptake.
Benefits
- Improves insulin sensitivity
- Supports healthy blood sugar levels
- Provides antioxidant support
- Helps manage diabetic neuropathy and fatigue
- Adjunct support to standard diabetes management
Recommended Dosage:
Take one tablet twice daily or as advised by a healthcare professional.
Description
Glyx Tablet is a dietary supplement formulated to support blood sugar regulation and enhance insulin sensitivity. It is designed to complement healthy lifestyle and dietary management for individuals seeking balanced glucose metabolism.
Key Active Ingredients
Bryophyllum Pinnatum Extract Supports blood sugar balance and beta-cell protection.
Fenugreek Extract Helps reduce glucose absorption and supports HbA1c control.
Alpha-Lipoic Acid Supports nerve health and reduces oxidative stress.
Chromium Picolinate Enhances insulin receptor activity and glucose uptake.
Benefits
- Improves insulin sensitivity
- Supports healthy blood sugar levels
- Provides antioxidant support
- Helps manage diabetic neuropathy and fatigue
- Adjunct support to standard diabetes management
Recommended Dosage:
Take one tablet twice daily or as advised by a healthcare professional.
Recently Viewed
3 Plus 1 CAVERNOS CAPSULE
3 Plus 1 SERMIXEED SACHET
Reviews
There are no reviews yet.